Client Opportunity

X4 is focused on restoring healthy immune system function by developing novel therapeutics to treat rare diseases. X4 has first-in-class, oral, small molecule therapeutics that are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. 

Their leadership team partnered with The Bowdoin Group to help bring in a VP of US Commercial with clinical and commercial experience and excellent knowledge of U.S. and Europe’s clinical, regulatory processes, and ICH guidance. The client’s goal was to engage with a strategic candidate who would be responsible for running X4’s regulatory submissions processes.  

The perfect candidate:

  • Executive leader with exceptional commercial leadership and marketing strategy experience in the rare disease space; Ability to build and lead high performing commercial teams
  • Past experience working for a public pharma or biotech company
  • Willingness to be strategic and hands-on, as well as the ability to remain flexible around the interpretation of regulations

The TBG Process

  • Build a list of rare disease pharmaceutical companies in the Greater Boston area and then identify all Commercial leaders at the Director, Vice President, and Senior Vice President levels
  • Expand to look at the Commercial leaders of oncology and immunology companies in the Greater Boston area
  • Network with leaders in the space 

  • Services:
    • Executive Search
  • Placements:
    • VP of US Commercial
  • Employee Count:
    • 50-99
  • Funding Rounds:
    • Post-IPO Equity

Client Result

After interviewing six qualified & strong candidates, the X4 team welcomed their new VP of US Commercial in August 2021.